The high mutation rate of RPL22/eL22 was also confirmed in other studies on T-acute lymphoblastic leukemia (T-ALL), endometrial and colorectal carcinomas[3, 4]. This evidence concerns the gene RPL22 and acute lymphoblastic leukemia.